Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA
Executive Summary
Watson Pharmaceuticals expects the overactive bladder patch Oxytrol to be cleared by FDA in the first quarter of 2003, following receipt of a "not approvable" letter March 26
You may also be interested in...
Somerset Emsam Safety Data Should Be Collected To Remove Restrictions
Somerset should amass safety data on its Emsam (selegiline) patches that would allow FDA to remove dietary restrictions on all strengths of the major depression therapy, the Psychopharmacologic Drugs Advisory Committee said Oct. 26
Somerset Emsam Safety Data Should Be Collected To Remove Restrictions
Somerset should amass safety data on its Emsam (selegiline) patches that would allow FDA to remove dietary restrictions on all strengths of the major depression therapy, the Psychopharmacologic Drugs Advisory Committee said Oct. 26
Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge
Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents